secwatch / observer

8-K filed October 22, 2025, 7:59 PM ET ticker TERN CIK 0001831363

other material confidence high sentiment negative materiality 0.90

Terns Pharma discontinues obesity drug TERN-601 after Phase 2 miss; liver enzyme signals seen

Terns Pharmaceuticals, Inc.

Max placebo-adjusted weight loss 4.6% (p<0.0001) at 500 mg dose; 11.9% discontinued due to AEs.
Grade 3 liver enzyme elevations in 3 participants post-treatment, 2 deemed drug-related.
Company will not advance TERN-601 or further invest in metabolic assets.
Reiterates focus on TERN-701 for CML with clinical data expected this quarter.
GI AEs most common: nausea 56%, vomiting 26.9%; all mild/moderate and dose-related.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-245404
form_type: 8-K
ticker: TERN
cik: 0001831363
company_name: Terns Pharmaceuticals, Inc.
filed_at: 2025-10-22T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.682658+00:00
generated_at: 2026-05-17T02:48:21.366784+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-245404
json_url: https://secwatch.observer/filing/0001193125-25-245404.json
markdown_url: https://secwatch.observer/filing/0001193125-25-245404.md
text_url: https://secwatch.observer/filing/0001193125-25-245404.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/0001193125-25-245404-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831363/000119312525245404/d14463d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FULC

Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review

Fulcrum Therapeutics, Inc. June 1, 2026, 4:05 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

GPRO

GoPro refiles financials with going-concern warning; potential defaults on debt

GoPro, Inc. June 1, 2026, 9:12 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

STSS

Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South

Sharps Technology Inc. June 1, 2026, 8:15 AM ET other_material Items 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment

Charlotte's Web Holdings, Inc. June 1, 2026, 5:13 PM ET other_material Items 5.02, 5.07, 8.01

same SEC item: 8.01 same event type: other_material similar materiality

Filing page SEC filing

MDAI

Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026

Spectral AI, Inc. June 1, 2026, 4:01 PM ET other_material Items 5.07, 7.01, 9.01

same SEC item: 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-245404

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.